My laboratory is interested in understanding the role of the intestinal microbiome in mediating liver disease outcomes via the gut-liver axis. Specifically, medical therapy for metabolic dysfunction-associated steatotic liver disease (MASLD) and autoimmune liver disease is currently an area of unmet need. By studying the effects of the microbiome in both the liver and intestinal microenvironment, this may highlight new therapeutic avenues that can be further studied and ultimately utilized in the patient care setting.